 |
| SL-03 |
Clinical Research and New Drug Development in Japan |
| |
|
Yasuo Ikeda (Dept. Internal Med., Keio Univ. Sch. Med.) |
 |
|
|
| SL-04 |
Chemistry at the Chemistry-Biology Interface |
| |
|
Dale L. Boger (Dept. Chem., The Scripps Res. Instit. Chem. Biol.) |
|
|
|
| SL-05 |
Systems Biology of Transcriptional Activation in the Human Cell |
| |
|
Tatsuhiko Kodama (Res. Center for Advanced Sci. Tech, The Univ. Tokyo) |
|
|
|
| SL-07 |
Acute Lymphoblastic Leukemia Patients Carrying the t(4;11) translocation: Pathophysiology, Epigenetic Mechanisms and Novel Treatment Strategies |
| |
|
T.Dingermann (Dept. Pharm. Biol., Univ. Frankfurt) |
|
|
|
| SL-08 |
Pipinixic Acid Derivatives as Potent Dual
Agonist of the Peroxisome Proliferator
Activated Receptor Alpha and Gamma |
| |
|
M.Schubert-Zsilavecz (Instit. Pharm. Chem., Univ. Frankfurt) |
|
|
|
| SL-09 |
Transforming Drug Discovery and Development by the Innovation with Biotechnology and Changes in Society |
| |
|
Mitsuru Miyata (Nikkei Business Publications, Inc.) |
|
|
|
| SL-11 |
Opportunities with Nasal Drug Delivery |
| |
|
Sveinbjorn Gizurarson (Fac. Pharmacy, Univ. Iceland) |
|
|
|
| SL-13 |
Education for the Pharmacists and
Pharmaceutical Scientists in Europe;
What, Why, When, Where・・・ |
| |
|
D. J. A. Crommelin (Dutch Top Institute Pharma. TI Pharma) |
|
|
|
| SL-14 |
Mechanism-Based PK-PD Modeling for Prediction of Efficacy-Safety in Drug Development |
| |
|
Meidert Danhof (Leiden Univ.) |
|
|
|
| SL-15 |
Pharmacy Education in the UK |
| |
|
Soraya Dhillon (Univ. Hertfordshire) |
|
|
|
| SL-16 |
Progress on Chemotherapy for Gastrointestinal Cancer and the Role of Pharmacist |
| |
|
Atsushi Ohtsu (Hospital East, Nat.Cancer Center ) |
|
|
|
| SL-18 |
Invention of Transition Metal-Catalyzed Carbon-Carbon Bond Forming Reactions |
| |
|
Tamejiro Hiyama (Grad. Sch. Engineering, Kyoto Univ.) |
|
|
|
| SL-19 |
New Catalysis Concepts |
| |
|
David W. C. MacMillan (Princeton Univ.) |
|
|
|
| SL-20 |
What is Required for Pharmaceutical Education |
| |
|
Nobuhiko SAITO (Japan Society for Medical Education) |
|
|
|
| SL-21 |
Dynamic Nuclear Polarization MRI for Monitoring Cancer Treatment Response |
| |
|
Murali Krishna Cherukuri (Center for Cancer Research, Nat. Cancer Instit.) |
|
|
|
| SL-22 |
Bioactive Compounds from Marine Organisms and
the Challenge of Discovery at the Nanomole-Scale |
| |
|
Tadeusz F. Molinski (Dept. Chem. Biochem., Univ. California) |
|
|
|
| SL-24 |
Synthetic Biologics: A New Class Drugs for
“Undruggable Targets” |
| |
|
Gregory L. Verdine (Dept. Chem. Chem. Biol., Harvard Univ.) |
|
|
|
|
|
